Registration Info

This is a 1-day meeting and will provide 6 CE/CME credits.

Conference Registration Fee

$129

Register Now >>

Non-Clinicians / Medical Office Support Staff / Industry Participants

In order to maintain the clinical nature of the conference, nonclinicians—including, but not limited to, office managers, billing specialists, receptionists, and administrative staff; guests, spouses, friends, and/or family members—may not attend PAINWeekEnd.

COVID-19 Information

Marriott Commitment

The Westin Galleria Dallas is committed to keeping conference attendees safe. Click here for more information.

Venue

Unfortunately, we do not have discounts available on hotel rooms. Please contact the hotel directly should you require accommodations.

The Westin Galleria Dallas
13340 Dallas Parkway
Dallas, TX 75240

View hotel website >>

Get Directions using Google Maps

Schedule

Faculty and courses are subject to change. Please refer to the online schedule below for the most recent course descriptions.

To view the schedule below, click on the + sign next to the day of the conference to expand the conference agenda. Click on the + signs within the agenda to view the course description, UAN number, and AANP pharmacology credits.

*not certified for credit

Saturday, June 5, 2021

  • REGISTRATION & EXHIBITS

    Coffee will be served.

  • Nonopioid Analgesics, Adjuvants, and Antidepressants

    Nonopioid analgesics are considered first-line therapy for most chronic pain syndromes. A strong recall of these agents’ safety and efficacy profiles is paramount for today’s pain practitioner. This course will provide an in-depth look at each of the agents within these drug classes, their potential role in pain management, and available data supporting their use. Additionally, clinically relevant monitoring will be discussed.

    • UAN: 0530-0000-21-059-L04-P
    • AANP Rx Hours: 1.0

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Breakfast will be served.

  • BREAK & EXHIBITS

  • Interventional Pain Management: Opioid-Sparing Technologies

    The ancient Sumerians first cultivated the poppy plant for its opium in 3000 BC. The analgesic properties of opium were formalized into morphine and later commercialized by Merck Pharmaceuticals in 1827. Morphine and its derivatives have been effectively used for treating acute pain. In recent years, however, the overuse of opioids to treat chronic nonmalignant pain has contributed to the prescription opioid epidemic. As society has recognized this problem and our government has stepped into opioid crisis efforts, we turn to technology in treating chronic pain as an alternative to opioid medications. This presentation is targeted for general practitioners and current pain management physicians. We will explore the evolution of pain medicine leading up to the current and future opioid-sparing interventional pain treatment options. Specifically, we will focus on electroceuticals (spinal cord stimulation, peripheral nerve stimulation, vagus nerve stimulation), minimally invasive spinal decompression spacers, and percutaneous sacroiliac joint fusion.

    • UAN: 0530-0000-21-060-L04-P
    • AANP Rx Hours: 0.0

  • Drugs, Documentation, and DEA: Improving Your Charting of Prescribing Rationale in 2021 and Beyond

    Overlooking the importance of carefully documenting the rationale for the use of a controlled medication can land a prescriber in hot water with their licensing board or the DEA. This course will focus on what it takes to move beyond the problems associated with both EMR and handwritten medical charts, and into the documentation of cogent notes signaling proper patient evaluation, including risk evaluation, rationale for the use of controlled medication, and ongoing encounters with the patient.

    • UAN: 0530-0000-21-005-L03-P
    • AANP Rx Hours: 0.0

  • FACULTY Q&A

  • BREAK & EXHIBITS

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Lunch will be served.

  • Spinal Stenosis: Epidemiology, Pathophysiology, and Treatment

    Degenerative lumbar spinal stenosis (LSS) is the most common form of acquired spinal stenosis caused by biomechanical narrowing of the spinal canal and the associated neuroforamen that eventually lead to compression of neural fibers resulting in pain and disability. Neurogenic claudication as a result of lumbar spinal stenosis is a common chronic pain condition that is often difficult to treat due to paucity of effective minimally invasive options. Patients who exhaust conservative means usually have short term pain relief with epidural steroid injections prior to being offered open lumbar decompression surgery. LSS is a progressive, age related degenerative process that causes narrowing of the lumbar spinal canal. More than 1.2 million patients in the US are diagnosed with spinal stenosis each year, and the number is expected to rise as our population matures. This presentation will focus on the epidemiology, pathophysiology, and treatment options available for spinal stenosis. There will be discussions relating to the health economics of spinal stenosis as it pertains to disability and cost of treatment. We will specifically focus on some of the recently available minimally invasive options such as indirect interspinous decompression and minimally invasive lumbar decompression.

    • UAN: 0530-0000-21-010-L08-P
    • AANP Rx Hours: 0.0

  • BREAK & EXHIBITS

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Refreshments will be served.

  • Rational Polypharmacy

    Rational polypharmacy or the use of multiple medications to manage the same disease state or condition has been a part of treatment approaches for chronic pain for many years. This course will review the concept of rational polypharmacy as it applies to the treatment of migraine, neuropathic pain, and musculoskeletal pain conditions.

    • UAN: 0530-0000-21-061-L04-P
    • AANP Rx Hours: 0.0

  • Through the Lens of Experts: Meaningful Risk Mitigation and Patient Education

    Those who have been on either side of a courtroom battle on chronic opioid therapy have seen experts and lawyers spend a great deal of time arguing about the extent and nature of risk mitigation and patient education necessary to demonstrate that the prescriber issued a valid controlled substance prescription. The focus of expert testimony is on whether the prescriber engaged in meaningful risk evaluation and monitoring practices, and whether the prescriber individualized medical care for the patient, based on specific history and behaviors as treatment went on. This course will use published medical expert testimony and common expert reports of illegal and insufficient risk mitigation and patient education. The main goal is to facilitate a prescriber's self-audit of risk mitigation practices and to help attendees improve documentation of risk mitigation protocols and patient education efforts. A proactive approach to meaningful risk mitigation is necessary for protecting patient access to quality pain care and creating a framework within which other practitioners may confidently assume care for patients when necessary, and demonstrating appropriate prescribing of chronic opioid therapy.

    • UAN: 0530-0000-21-062-L03-P
    • AANP Rx Hours: 0.4

SPONSORED PROGRAMS

To accompany and enrich your experience at the PAINWeekEnd conference, be sure to attend one or more of the sponsored programs, which are scheduled during breakfast, lunch, and afternoon "Brain Food" time slots in the schedule. There is NO ADDITIONAL CHARGE to attend these program sessions!